AAAAAA
Results:
1-12
|
Results: 12
Authors:
Afargan, M
Janson, ET
Gelerman, G
Rosenfeld, R
Ziv, O
Karpov, O
Wolf, A
Bracha, M
Shohat, D
Liapakis, G
Gilon, C
Hoffman, A
Stephensky, D
Oberg, K
Citation: M. Afargan et al., Novel long-acting somatostatin analog with endocrine selectivity: Potent suppression of growth hormone but not of insulin, ENDOCRINOL, 142(1), 2001, pp. 477-486
Authors:
Fjallskog, MLH
Granberg, DPK
Welin, SLV
Eriksson, C
Oberg, KE
Janson, ET
Eriksson, BK
Citation: Mlh. Fjallskog et al., Treatment with cisplatin and etoposide in patients with neuroendocrine tumors, CANCER, 92(5), 2001, pp. 1101-1107
Authors:
Portela-Gomes, GM
Stridsberg, M
Grimelius, L
Oberg, K
Janson, ET
Citation: Gm. Portela-gomes et al., Expression of the five different somatostatin receptor subtypes in endocrine cells of the pancreas, APPL IMMUNO, 8(2), 2000, pp. 126-132
Authors:
Janson, ET
Westlin, JE
Ohrvall, U
Oberg, K
Lukinius, A
Citation: Et. Janson et al., Nuclear localization of In-111 after intravenous injection of [In-111-DTPA-D-Phe(1)]-octreotide in patients with neuroendocrine tumors, J NUCL MED, 41(9), 2000, pp. 1514-1518
Authors:
Cunningham, JL
Lopez-Egido, JR
Janson, ET
Eriksson, B
Oberg, K
Gobl, AE
Citation: Jl. Cunningham et al., Transmembrane protein tyrosine phosphatase IA-2 (ICA512) is expressed in human midgut carcinoids but is not detectable in normal enterochromaffin cells, J ENDOCR, 164(3), 2000, pp. 315-322
Authors:
Janson, ET
Oberg, K
Citation: Et. Janson et K. Oberg, Somatostatin receptor ligands and their use in the treatment of endocrine disorders, CUR PHARM D, 5(9), 1999, pp. 693-705
Authors:
Oberg, K
Janson, ET
Eriksson, B
Citation: K. Oberg et al., Tumour markers in neuroendocrine tumours, ITAL J GAST, 31, 1999, pp. S160-S162
Authors:
Janson, ET
Kalkner, KM
Eriksson, B
Westlin, JE
Oberg, K
Citation: Et. Janson et al., Somatostatin receptor scintigraphy during treatment with lanreotide in patients with neuroendocrine tumors, NUCL MED BI, 26(8), 1999, pp. 877-882
Authors:
Janson, ET
Eriksson, B
Oberg, K
Skogseid, B
Ohrvall, U
Nilsson, S
Westlin, JE
Citation: Et. Janson et al., Treatment with high dose [In-111-DTPA-D-PHE1]-octreotide in patients with neuroendocrine tumors - Evaluation of therapeutic and toxic effects, ACTA ONCOL, 38(3), 1999, pp. 373-377
Authors:
Lukinius, A
Ohrvall, U
Westlin, JE
Oberg, K
Janson, ET
Citation: A. Lukinius et al., In vivo cellular distribution and endocytosis of the somatostatin receptor-ligand complex, ACTA ONCOL, 38(3), 1999, pp. 383-387
Authors:
Georgii-Hemming, P
Stromberg, T
Janson, ET
Stridsberg, M
Wiklund, HJ
Nilsson, K
Citation: P. Georgii-hemming et al., The somatostatin analog octreotide inhibits growth of interleukin-6 (IL-6)-dependent and IL-6-independent human multiple myeloma cell lines, BLOOD, 93(5), 1999, pp. 1724-1731
Authors:
Zhou, U
Gobl, A
Wang, S
Jacobsen, MB
Janson, ET
Haines, GK
Radosevich, JA
Oberg, K
Citation: U. Zhou et al., Expression of p68 protein kinase and its prognostic significance during IFN-alpha therapy in patients with carcinoid tumours, EUR J CANC, 34(13), 1998, pp. 2046-2052
Risultati:
1-12
|